Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

Novo Nordisk's Obesity Drug Wegovy May Be Double Blockbuster Already in 2022, Danske Says

13/10 14:51


  • (PLX AI) – Novo Nordisk's new obesity drug, Wegovy, may reach double blockbuster status already next year, analysts at Danske Bank said in a research note.
  • • That is almost double their previous forecast for the drug
  • • Wegovy sales have taken off from the start in the United States, with the company struggling to meet demand
  • • NOTE: Novo said yesterday that it has increased production of Wegovy and is on track to stabilize supply by early next year
  • • Novo faces insulin price cuts in China, but the massive boost from Wegovy should still see the Danish drugmaker post sales growth of 11.9% next year, Danske said
  • • Danske rates Novo buy, with price target DKK 735, which implies 15% upside